

CXCL1 Antibody (C-Term)
Peptide-affinity purified goat antibody
Catalog # AF3020a**Specification**

CXCL1 Antibody (C-Term) - Product Information

Application	E
Primary Accession	P09341
Other Accession	NP_001502.1 , 2919
Predicted	Human
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	11301

CXCL1 Antibody (C-Term) - Additional Information**Gene ID** 2919**Other Names**

Growth-regulated alpha protein, C-X-C motif chemokine 1, GRO-alpha(1-73), Melanoma growth stimulatory activity, MGSA, Neutrophil-activating protein 3, NAP-3, GRO-alpha(4-73), GRO-alpha(5-73), GRO-alpha(6-73), CXCL1, GRO, GRO1, GROA, MGSA, SCYB1

Dilution

E~~N/A

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

CXCL1 Antibody (C-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

CXCL1 Antibody (C-Term) - Protein Information**Name** CXCL1**Synonyms** GRO, GRO1, GROA, MGSA, SCYB1**Function**

Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on

endothelial cells in an autocrine fashion. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity.

Cellular Location

Secreted.

CXCL1 Antibody (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

CXCL1 Antibody (C-Term) - Images**CXCL1 Antibody (C-Term) - References**

Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer
Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O Clin. Cancer Res. 2008 May 14 (9): 2579-87 PMID: 18451219